# Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

> **NCT04889118** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 131 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Placebo for lenvatinib

## Key facts

- **NCT ID:** NCT04889118
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2023-01-18
- **Final completion:** 2024-11-01
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04889118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04889118, "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04889118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*